Aberrant expression of oncogenic transcription factors (Sp1, HMGA1, TP53, BRCA2, WT1, VHL) [10,11,12,13] or fusion gene products (TMPRSS2::ERG, EWS::WT1, EWS::FLI1, PAX3::FKHR) might alter IGF axis activity in cancer [14,15,16,17]. This evidence concerns the gene EWSR1 and cancer.